12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cycloset bromocriptine mesylate regulatory update

Santarus Inc. (NASDAQ:SNTS, San Diego, Calif.) and VeroScience announced that Cycloset bromocriptine was included in the diabetes management algorithm published by the American Association of Clinical Endocrinologists (AACE). The algorithm recommended dual therapy to include Cycloset as an option in combination...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >